It’s difficult to quantify the prevalence of unethical practices in behavioral health, but most agree it's more a case of criminal enterprise than treatment centers gone bad. See the survey results with expert analysis.
ASAM is accepting public comment on a drug testing appropriateness document that is being developed to provide guidance on drug testing in diagnosis, treatment and promotion of recovery from addiction.
In response to advocacy groups and congressional leaders, the Drug Enforcement Administration halted its attempt to place kratom on the list of Schedule I drugs, however, experts recommend more research on its pharmacology moving forward.
September 13, 2016 | Julie Miller, Editor in Chief
Commercial health insurers paid treatment centers and other providers $445.7 million to treat plan members’ opioid dependence and abuse in 2015, demonstrating a 1,375% spending increase over five years.
As part of a $300 million settlement, UnitedHealthcare will no longer require policyholders to demonstrate abstinence from drugs and alcohol for six months before receiving coverage for a costly hepatitis C medication.
Here's a roundup of 2015 earnings reports for Acadia, American Addiction Centers and Universal Health Services. Acquisitions and new growth after a potential change to the IMD exclusion were key issues.
October 8, 2015 | Gary A. Enos. Contributing Editor
Drug testing company Calloway Laboratories, which in recent years had been embroiled in controversies over improper government payments, is citing "unforeseen circumstances" in its decision to cease operation on Oct. 16.